RxDoctor Payments Data

Amanda Dupuis, APRN

Family · Raleigh, NCNPI 1124690896

Payments from drug & device makers

$4,219in general payments, 2019–2025

Across 218 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$803
  • Lilly USA, LLC$485
  • AstraZeneca$343
  • Boehringer Ingelheim$273
  • Dexcom, Inc.$245
  • Antares Pharma, Inc.$182
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$4,207100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,219 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$3,582
Medicare patients
20
Services billed
43

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide66$70,305
JardianceEmpagliflozin38$22,986
XareltoRivaroxaban12$6,676
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$6,444
VascepaIcosapent Ethyl16$5,839
FarxigaDapagliflozin Propanediol16$5,681
Humalog Kwikpen U-100Insulin Lispro21$4,582
Insulin Lispro Protamine MixInsulin Lispro Protamin/Lispro17$2,997
Atorvastatin Calcium279$2,407
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$2,390
Albuterol Sulfate HfaAlbuterol Sulfate69$2,149
Metformin Hcl237$2,006
Ultra-Fine Nano Pen NeedlePen Needle, Diabetic32$1,997
Rosuvastatin Calcium34$1,784
Levothyroxine Sodium136$1,394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$485$70,30566 claims
Boehringer IngelheimJardiance$273$22,98638 claims
Johnson & JohnsonXarelto$152$6,67612 claims
AstraZenecaFarxiga$343$5,68116 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$157$1,394136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.

Other family in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →